Inclusion Criteria:

1. Any patient with a hematological or oncological diagnosis in which allogeneic
hematopoietic stem cell transplantation (HSCT) is thought to be beneficial.

1. Patients without morphological or molecular evidence of disease or

2. If the patient has evidence of disease the disease burden must be minimal (at
least PR) and the disease must be chemoresponsive

3. For patients with MDS the inclusion criteria is specifically as follows:

- For patients with RA or RARS or isolated 5q- they can proceed to transplant
without any treatment.

- For patients with RAEB-1, RCMD+/-RS, or MDS NOS must have stable disease
for 6 months (as documented by serial bone marrow examinations) in the
absence of any therapy but growth factors or transfusion support. Patients
who require treatment to "control their disease" must show
chemo-responsiveness.

- For patients with CMML or RAEB-2 they must demonstrate chemoresponsiveness.

- Chemo-responsiveness is defined as a blast percentage decrease by at least
5 percentage points and there must be less than 10% blasts after treatment
and at the time of transplant, if there are more than 10% blasts at any
point during the disease course.

- Chemo-responsiveness must also include at least one of the following if
applicable:

- A cytogenetic response

- A well-documented decrease in transfusion requirements.

2. Patients must have a related donor who is zero, one, two, three, or four antigen
mismatched at the human leukocyte antigen (HLA) -A; B; C; DR loci or an unrelated
donor up to a two allele mismatch. DNA will be retained by the tissue typing
laboratory for possible typing for DQ and DP.

3. All patients must have adequate organ function:

1. Patients with related donors must have an left ventricular ejection fraction
(LVEF) of >35%. Patients with unrelated donors must have an LVEF >45%. Patients
with LVEF < or = 50% and all patients with symptoms or history of heart failure
or coronary artery disease must have a stress echo or equivalent test and a
cardiological evaluation.

2. Patients with related donors must have a diffusing capacity of the lung for
carbon monoxide (DLCO) >35% of predicted corrected for hemoglobin. Patients with
unrelated donors must have a DLCO >45% of predicted corrected for hemoglobin.
For related donors if the DLCO is less than 45% the ejection fraction (EF) must
be greater than 45% and vice versa.

3. Patients with related donors must have an adequate liver function as defined by
a serum bilirubin <3.0, aspartate transaminase (AST) and alanine transaminase
(ALT) <3.0X upper limit of normal. Patients with unrelated donors must have an
adequate liver function as defined by a serum bilirubin <1.8, AST and ALT < 2.5X
upper limit of normal. Exceptions may be granted for patients with "benign"
liver disorders such as Gilbert's disease.

4. Patients with related donors must have a creatinine of < or = 2mg/dl. Patients
with unrelated donors must have a creatinine clearance of > 60 ml/min/1.73 m2.

5. Patients with related donors must have a performance status > 60% (TJU
Karnofsky). Patients with unrelated donors must have a Performance status > 70%
(TJU Karnofsky).

6. Patients with related donors must have a Hematopoietic Cell
Transplantation-Specific Comorbidity Index (HCT-CI) Score < 6 Points. Patients
with unrelated donors must have a HCT-CI Score < 5 Points.

7. Patients must be willing to use contraception if they are of childbearing
potential.

8. Patients must be able to give informed consent or have a care giver who can give
consent.

9. Patients with marrow based disease will require a bone marrow aspiration/biopsy
within 30 days of admission.

Exclusion Criteria:

1. Patients with related donors who have a performance status < 60% (the patients', not
the donor's performance status). Patients with unrelated donors who have a
performance status < 70% (TJU Karnofsky).

2. Patients with related donors who have a HCT-CI Score > 6 Points. Patients with
unrelated donors who have a HCT-CI Score > 5 Points

3. Patients with related donors who have a combination of Performance status of < 70%
(TJU Karnofsky) and an HCT-CI of 4 points or more. Patients with unrelated donors
with a combination of Performance status of < 80% (TJU Karnofsky) and an HCT-CI of 4
points or more.

4. HIV positive

5. Patients with active involvement of the central nervous system with malignancy.
Patients with a disease with potential for CNS involvement should have documentation
of the lack of CNS involvement via lumbar puncture or similar procedure performed
within two months of admission or as per TJU standard practice guidelines.

6. Patients with a psychiatric disorder that would preclude patients from complying with
the protocol even with a caregiver. Patients with a lack of social support that would
interfere with the ability to receive appropriate medical care will also be excluded.

7. Pregnancy

8. Patients with life expectancy of < 6 months for reasons other than their underlying
hematological/oncological disorder

9. Patients who have received alemtuzumab within 8 weeks of the transplant admission, or
who have recently received horse or rabbit ant-thymocyte globulin and have an ATG
level of > 2 μg/ml. Patients on systemic corticosteroids at a dose equivalent of
prednisone 7.5mg/day or higher.

10. Patients who cannot receive cyclophosphamide.

11. Patients with evidence of another malignancy, exclusive of a skin cancer that
requires only local treatment, should not be enrolled on this protocol.

12. Patients with refractory disease.

13. Patients with preformed antibodies to their donors.

14. Patients who require supplemental oxygen other than for sleep apnea will be excluded.